Background Sequence variants in the 13-adrenergic receptor （ADRB） genes have a close relationship with the development of coronary artery disease （CAD） and the patient＇s prognosis. However, there is a lack of dat...Background Sequence variants in the 13-adrenergic receptor （ADRB） genes have a close relationship with the development of coronary artery disease （CAD） and the patient＇s prognosis. However, there is a lack of data on the role of the variants in ADRBs genes in Han Chinese patients with CAD. We aimed to investigate the association of genetic variants in the ADRB1 and ADRB2 genes with the incidence of major adverse cardiac event （MACE） in Han Chinese patients with CAD. Methods A total of 545 Han Chinese patients with CAD undergoing percutaneous coronary intervention （PCI） were recruited to the study and followed for one year. Three variant sites in ADRB1 （rs1801253） and ADRB2 （rs1042713 and rs1042714） were genotyped. The effect of the ADRB1 and ADRB2 genotypes on MACE within one year was assessed. Results There were 47 cases of MACE during follow-up. There was no significant difference in the incidence of MACE among patients carrying different genotypes of the three variants in ADRB1 and ADRB2 （Log-rank, all P 〉0.05）. Cox regression analysis showed no association between three variants in ADRB1 and ADRB2 genes and the incidence of MACE during one-year follow-up, the adjusted hazard ratios （95% confidence interval） for rs1801253, rs1042713 and rs1042714 were 1.05 （0.54-2.02）, 1.24 （0.58-2.64）and 1.66 （0.81-3.42）, respectively. Conclusion Our data did not support a relationship between the three polymorphisms of ADRB1 （rs1801253） and ADRB2 （rs1042713 and rs1042714） genes and risk of subsequent cardiovascular events after PCI in Han Chinese patients with CAD.展开更多
Background Glucocorticoid signaling exerts major roles in inflammation, metabolism and depression, which are three crucial factors accompanying or underlying coronary heart disease. Although accumulating evidence indi...Background Glucocorticoid signaling exerts major roles in inflammation, metabolism and depression, which are three crucial factors accompanying or underlying coronary heart disease. Although accumulating evidence indicates the influence of glucocorticoids on the pathology and treatment of coronary heart disease, there is still a dearth of pharmaceutical mechanisms for this relationship. This study aimed to investigate the influence of drug treatment on glucocorticoid receptor levels in coronary heart disease. Methods Eighty hospitalized patients （average age （59.0＋7.5） years, 46 male and 34 female） with coronary heart disease were categorized into four groups with 20 members in each according to one of the four drugs they were treated with. The four drugs were： nitrated derivative isosorbide dinitrate, the beta-adrenergic receptor blocker metoprolol, the calcium antagonist nifedipine, and the HMG-CoA reductase inhibitor Iovastatin. Glucocorticoid receptor protein levels of peripheral blood lymphocytes were tested using immunoblotting analysis before and after one month of treatment. Results Immunoblotting analysis showed increased glucocorticoid receptor levels after treatment with metoprolol and nifedipine. There were no statistically significant changes of glucocorticoid receptor levels after treatment with isosorbide dinitrate or Iovastatin, although there were trends of up-regulation of glucocorticoid receptor expression after both treatments. Conclusions Both the beta-blocker and the calcium blocker can increase glucocorticoid receptor levels after chronic administration. This effect suggests a mechanism for their anti-inflammatory and other therapeutic roles for coronary heart disease and comorbid disorders.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China （No. 81072701 and No. 81373486）, the Natural Science Foundation of Guangdong Province （No. S2011010005830） and Science and Technology Development Projects of Guangdong Province, China （No. 201 lb061200030 and No. 2012A030400062）. Conflict of interest： none.
文摘Background Sequence variants in the 13-adrenergic receptor （ADRB） genes have a close relationship with the development of coronary artery disease （CAD） and the patient＇s prognosis. However, there is a lack of data on the role of the variants in ADRBs genes in Han Chinese patients with CAD. We aimed to investigate the association of genetic variants in the ADRB1 and ADRB2 genes with the incidence of major adverse cardiac event （MACE） in Han Chinese patients with CAD. Methods A total of 545 Han Chinese patients with CAD undergoing percutaneous coronary intervention （PCI） were recruited to the study and followed for one year. Three variant sites in ADRB1 （rs1801253） and ADRB2 （rs1042713 and rs1042714） were genotyped. The effect of the ADRB1 and ADRB2 genotypes on MACE within one year was assessed. Results There were 47 cases of MACE during follow-up. There was no significant difference in the incidence of MACE among patients carrying different genotypes of the three variants in ADRB1 and ADRB2 （Log-rank, all P 〉0.05）. Cox regression analysis showed no association between three variants in ADRB1 and ADRB2 genes and the incidence of MACE during one-year follow-up, the adjusted hazard ratios （95% confidence interval） for rs1801253, rs1042713 and rs1042714 were 1.05 （0.54-2.02）, 1.24 （0.58-2.64）and 1.66 （0.81-3.42）, respectively. Conclusion Our data did not support a relationship between the three polymorphisms of ADRB1 （rs1801253） and ADRB2 （rs1042713 and rs1042714） genes and risk of subsequent cardiovascular events after PCI in Han Chinese patients with CAD.
文摘Background Glucocorticoid signaling exerts major roles in inflammation, metabolism and depression, which are three crucial factors accompanying or underlying coronary heart disease. Although accumulating evidence indicates the influence of glucocorticoids on the pathology and treatment of coronary heart disease, there is still a dearth of pharmaceutical mechanisms for this relationship. This study aimed to investigate the influence of drug treatment on glucocorticoid receptor levels in coronary heart disease. Methods Eighty hospitalized patients （average age （59.0＋7.5） years, 46 male and 34 female） with coronary heart disease were categorized into four groups with 20 members in each according to one of the four drugs they were treated with. The four drugs were： nitrated derivative isosorbide dinitrate, the beta-adrenergic receptor blocker metoprolol, the calcium antagonist nifedipine, and the HMG-CoA reductase inhibitor Iovastatin. Glucocorticoid receptor protein levels of peripheral blood lymphocytes were tested using immunoblotting analysis before and after one month of treatment. Results Immunoblotting analysis showed increased glucocorticoid receptor levels after treatment with metoprolol and nifedipine. There were no statistically significant changes of glucocorticoid receptor levels after treatment with isosorbide dinitrate or Iovastatin, although there were trends of up-regulation of glucocorticoid receptor expression after both treatments. Conclusions Both the beta-blocker and the calcium blocker can increase glucocorticoid receptor levels after chronic administration. This effect suggests a mechanism for their anti-inflammatory and other therapeutic roles for coronary heart disease and comorbid disorders.
